# A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

> **NCT05918822** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 32 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Maribavir Commercial Tablet Formulation
- **DRUG:** Maribavir Pediatric Powder-for-oral Suspension Formulation
- **DRUG:** Rabeprazole

## Key facts

- **NCT ID:** NCT05918822
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-25
- **Primary completion:** 2023-08-25
- **Final completion:** 2023-09-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918822, "A Study of Maribavir Pediatric Formulation in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05918822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*